Recent site activity

  • TORs
    edited by szipursky@path.org
  • Environmental Impact
    attachment from Oz Mansoor
    edited by Oz Mansoor
  • Home
    edited by dkristensen@path.org
    attachment from dkristensen@path.org
    edited by Oz Mansoor
    attachment from Oz Mansoor
    edited by szipursky@path.org
  • 2011vppag
    created by szipursky@path.org
  • TORs
    edited by szipursky@path.org
  • View All

Home

About VPPAG
VPPAG provides a forum for public sector and vaccine manufacturers – both from the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) and the Developing Country Vaccine Manufacturer’s Network (DCVMN) - to discuss and reach consensus on vaccine presentation and packaging issues to support the development of products suited to low and middle income country contexts.

VPPAG was established in 2007 by the GAVI Alliance to respond to an industry request on pneumococcal conjugate vaccine (PCV); this led to a paper used for the WHO target product profile for the Advance Market Commitment. In 2008, WHO took over the role of convening VPPAG, and the work of the group was broadened. By 2009, VPPAG had developed a draft generic preferred product profile (gPPP) to address the range of potential new vaccines in the development pipeline.

gPPP and PSPQ
The gPPP concept was taken up by WHO in 2010 and formed a key input into the Programmatic Suitability of vaccines for Prequalification (PSPQ) process. The VPPAG has also undertaken work to form recommendations for future vaccine presentation and packaging formats
for Human Papillomavirus vaccines and has responded to specific industry requests on vaccines in development through bilateral consultations.

Relationship with IPAC
While VPPAG does not issue any formal recommendations or have an official advisory role, VPPAG may, on the request of WHO, be asked to discuss and provide inputs on specific topics. The newly established Immunization Practices Advisory Committee (IPAC) to WHO has also established VPPAG as one of its standing committees. IPAC’s mandate is focused on providing operational level guidance for immunization programmes, including issues around vaccine handling, presentation and packaging. IPAC’s policy related deliberations will be shared with the Strategic Advisory Group of Experts (SAGE), which has the mandate to issue policy-related recommendations in consultation with WHO’s Director General.

2011
In 2011, VPPAG’s work will focus on reviewing the current guidelines and regulatory requirements for vaccine labels, and examining how to improve them so that key information is easily read and used by health care workers.

This site holds the public documents produced by VPPAG (as attachments (numbered) below, and in linked page):

1) Terms of Reference (2008), with list of members

2) VPPAG HPV paper

3) VPPAG report for pneumo TPP (see below) and comparsino of VPPAG recommendations with final TPP here.
4) Presentation on VPPAG given to TechNet 2010 meeting

5) VPPAG Presentation to IPAC on Vaccine Labeling Issues (April 2011)

**NEW**: The Vaccine Presentation Assessment Tool is now available online. Click here for more information.

See also:  Generic Preferred Product Profile (gPPP): Version 2.1 now available

Subpages (3): HPV Pneumo TPP Uniject
Č
ĉ
ď
Oz Mansoor,
Dec 2, 2008, 7:43 AM
ĉ
ď
Oz Mansoor,
Dec 2, 2008, 7:43 AM
ċ
ď
Oz Mansoor,
Dec 2, 2008, 7:42 AM
ć
ď
dkristensen@path.org,
Apr 12, 2011, 11:31 AM
ć
ď
Oz Mansoor,
Mar 15, 2011, 9:25 AM
Comments